国际医学
(000516)
| 流通市值：122.85亿 | | | 总市值：125.47亿 |
| 流通股本：22.14亿 | | | 总股本：22.61亿 |
| 报告期 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 3,343,661,725.08 | 2,209,788,795.81 | 1,059,092,457.42 | 2,710,961,725.73 |
| 营业收入 | 3,343,661,725.08 | 2,209,788,795.81 | 1,059,092,457.42 | 2,710,961,725.73 |
| 二、营业总成本 | 3,731,857,156.74 | 2,496,683,170.89 | 1,182,081,758.95 | 3,783,487,157.35 |
| 营业成本 | 3,048,279,680.34 | 2,038,310,879.08 | 972,385,400.75 | 2,888,976,558.84 |
| 税金及附加 | 54,158,533.46 | 36,571,541.64 | 17,693,158.51 | 38,609,826.5 |
| 销售费用 | 22,384,372.09 | 14,488,868.36 | 664,059.91 | 27,261,801.85 |
| 管理费用 | 432,418,091.22 | 289,047,496.84 | 142,089,144.84 | 624,756,574.93 |
| 研发费用 | 9,533,885.43 | 7,091,253.08 | 3,325,497.8 | 15,512,950 |
| 财务费用 | 165,082,594.2 | 111,173,131.89 | 45,924,497.14 | 188,369,445.23 |
| 其中:利息费用 | 169,729,410.18 | 113,615,519.36 | 50,039,603.75 | 190,534,071.3 |
| 其中:利息收入 | 7,269,449.75 | 4,697,980.45 | 3,036,234.16 | 11,482,988.26 |
| 加:公允价值变动收益 | 5,203,903.91 | 24,760,673.91 | 25,481,353.41 | -80,789,019.7 |
| 加:投资收益 | 119,835,383 | 2,184,722.89 | 64,115.65 | 17,455,901.01 |
| 资产处置收益 | -83,031.59 | -83,031.59 | - | 7,251,930.12 |
| 资产减值损失(新) | - | - | - | -4,205,412.05 |
| 信用减值损失(新) | -16,173,111.86 | -12,649,691.49 | - | -8,824,902.1 |
| 其他收益 | 2,871,232.38 | 2,435,313.56 | 2,233,810.05 | 9,035,160.76 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | -276,541,055.82 | -270,246,387.8 | -95,210,022.42 | -1,132,601,773.58 |
| 加:营业外收入 | 1,071,465.67 | 836,091.89 | 215,609.36 | 5,681,336.01 |
| 减:营业外支出 | 7,448,987.87 | 2,047,580.3 | 602,204.77 | 13,384,833.1 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | -282,918,578.02 | -271,457,876.21 | -95,596,617.83 | -1,140,305,270.67 |
| 减:所得税费用 | 312,893.36 | 165,057.17 | 142,932.43 | 55,034,231.22 |
| 六、净利润 | -283,231,471.38 | -271,622,933.38 | -95,739,550.26 | -1,195,339,501.89 |
| 持续经营净利润 | -366,047,313.76 | -243,267,215.39 | -82,748,249.6 | -994,984,022.06 |
| 终止经营净利润 | 82,815,842.37 | -28,355,717.99 | -12,991,300.66 | -200,355,479.83 |
| 归属于母公司股东的净利润 | -222,323,554.29 | -222,259,756.8 | -74,740,547.17 | -1,176,682,639.57 |
| 少数股东损益 | -60,907,917.09 | -49,363,176.58 | -20,999,003.09 | -18,656,862.32 |
| (一)基本每股收益 | -0.1 | -0.1 | -0.03 | -0.52 |
| (二)稀释每股收益 | -0.08 | -0.09 | -0.03 | -0.43 |
| 九、综合收益总额 | -283,231,471.38 | -271,622,933.38 | -95,739,550.26 | -1,195,339,501.89 |
| 归属于母公司股东的综合收益总额 | -222,323,554.29 | -222,259,756.8 | -74,740,547.17 | -1,176,682,639.57 |
| 归属于少数股东的综合收益总额 | -60,907,917.09 | -49,363,176.58 | -20,999,003.09 | -18,656,862.32 |
| 公告日期 | 2023-10-27 | 2023-08-24 | 2023-04-19 | 2023-04-19 |
| 审计意见(境内) | | | | 标准无保留意见 |